Clinical trials: Small Cell Lung Carcinoma Extensive Disease
Small-Cell Lung Cancer
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not…
- Trial name
- NCT00466466
- Testing
- Everolimus
- Where
- 6 sites in United States, France
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
- Trial name
- NCT01737502
- Testing
- Auranofin, Sirolimus, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Extensive-stage Small-cell Lung Cancer
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung…
- Trial name
- IDeate-Lung01 (NCT05280470)
- Testing
- Ifinatamab Deruxtecan (I-DXd)
- Where
- 58 sites in United States, China and 6 more
- Volunteers
- 187 people
- Sponsor
- Daiichi Sankyo
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.
- Conditions
- Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer, Lung Metastases, Recurrent Malignant Mesothelioma
- Trial name
- NCT01325753
- Testing
- cryotherapy, quality-of-life assessment
- Sponsor
- Wake Forest University Health Sciences
Depression, Lung Cancer
Depression Screening in Patients With Lung Cancer
RATIONALE: Screening tests may help doctors find depression in patients with lung cancer, allow doctors to recommend treatment for depression, and improve the patient's quality of life.
- Trial name
- NCT00404365
- Testing
- counseling intervention, screening questionnaire administration, study of socioeconomic and demographic variables
- Where
- 2 sites in United States
- Volunteers
- 241 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Thromboembolism
Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
RATIONALE: Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients with lung cancer. It is not yet known whether dalteparin is effective in preventing blood clots in patients with lung cancer.
- Trial name
- NCT00519805
- Testing
- dalteparin, quality-of-life assessment
- Where
- 60 sites in United Kingdom
- Volunteers
- 2,200 people
- Sponsor
- Velindre NHS Trust
Small Cell Lung Cancer
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
- Trial name
- NCT02289690
- Testing
- Veliparib, Carboplatin, Etoposide
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 221 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Lung Cancer
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00866086
- Testing
- questionnaire administration, computed tomography, radiation therapy treatment planning/simulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Small Cell Lung Cancer
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin (or carboplatin) and etoposide in patients with previously…
- Trial name
- NCT00403403
- Testing
- Bevacizumab, Chemotherapy
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
This is an open label, phase 2 clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetic (PK) profile, and immunogenicity of QL1706 plus carboplatin and etoposide as first-line therapy in patients with…
- Trial name
- NCT05309629
- Testing
- QL1706, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Extensive-stage Small-cell Lung Cancer
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the…
- Trial name
- NCT05071703
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Lung Cancer
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544674
- Testing
- PR104, F-18-fluoromisonidazole
- Where
- 18 sites in United States
- Volunteers
- 5 people
- Sponsor
- Proacta, Incorporated
Lung Cancer
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
The purpose of this study is to test the safety of study drug LDE225 at different dose levels. The investigators will be testing three different dose levels and the dose will depend on when the patients enters the study and which…
- Trial name
- NCT01579929
- Testing
- LDE225, Etoposide and Cisplatin
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung…
- Trial name
- NCT06217757
- Testing
- Low-dose radiotherapy, Etoposide, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan University
Extensive-stage Small Cell Lung Cancer
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen
- Trial name
- NCT03841136
- Testing
- anlotinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
This study will evaluate the efficacy and safety of metronomic oral paclitaxel combined with a PD-1 or PD-L1 inhibitor as maintenance therapy in patients with advanced lung cancer whose disease has not progressed after first-line…
- Trial name
- PULSE (NCT07744698)
- Testing
- Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab)
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Anhui Provincial Cancer Hospital
Lung Cancer
Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00006082
- Testing
- rubitecan
- Where
- France
- Volunteers
- 38 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC